TL;DR — Ca-AKG is a TCA cycle intermediate that doubles as a cofactor for the epigenetic enzymes (TETs, JMJDs) that reverse age-related DNA methylation drift. Mouse data shows 12–14% median lifespan extension; human metabolic data from 2024 confirms TCA flux and epigenetic signals. Take 1 g AM with breakfast; no pairing restrictions. Highest hallmark breadth per gram of any OTC compound on the TNiC panel.
What Ca-AKG does (and why it matters)
Alpha-ketoglutarate (AKG) occupies a rare position in aging biology: it is simultaneously a metabolic fuel and an epigenetic enzyme cofactor. Most interventions target one hallmark; AKG reaches three from a single metabolite.
AKG levels decline sharply with age — from roughly 400–500 µM in young adults to under 100 µM in adults over 65. This is not a passive loss. It creates a bottleneck in both TCA cycle flux and in the enzymatic machinery that actively reverses DNA and histone methylation marks.
Primary hallmarks targeted: Epigenetic alterations · Mitochondrial dysfunction · Stem cell exhaustion
Shahmirzadi et al. Cell Metabolism 2020 (PMID 32877690): Ca-AKG supplementation in C57BL/6J mice extended median lifespan by 12% (females) and reduced age-related frailty. Aging Cell 2024 (PMID 34847066): human supplementation in middle-aged adults improved metabolic markers, inflammatory cytokines, and biological ageHow old your cells act — which can differ from your birthday age. Full glossary → clock scores over 12 weeks.
Mechanism — metabolic fuel and epigenetic cofactor
2a. TCA cycle anaplerosis
AKG is a direct entry point into the tricarboxylic acid (Krebs) cycle — converted via glutamate or directly entering as α-ketoglutarate. This anaplerotic role refuels the cycle when key intermediates are depleted, which happens chronically in aged cells with impaired mitochondrial substrate supply.
| TCA role | Effect | Hallmark link |
|---|---|---|
| Acetyl-CoA generation | Fuels citrate synthase step | Mitochondrial energy |
| Succinyl-CoA upstream | Supports heme synthesis | Proteostasis |
| Glutamine/glutamate precursor | Ammonium detox, neurotransmitter support | Communication |
2b. Epigenetic enzyme cofactor
α-Ketoglutarate is a mandatory obligate cofactor for a family of iron- and oxygen-dependent dioxygenases:
| Enzyme family | Function | Age-related effect of low AKG |
|---|---|---|
| TET1/2/3 | 5-methylcytosine oxidation → DNA demethylation | Methylation drift, clock aging |
| JMJ-domain demethylases | H3K4/K9/K27 histone demethylation | Chromatin stiffening |
| PHD (prolyl hydroxylase) | HIF-1α degradation in normoxia | Hypoxia-like signaling |
| Collagen P4Hs | Proline hydroxylation in collagen | Extracellular matrix aging |
When AKG is low, TET enzymes cannot complete the demethylation cycle that resets aging-associated hypermethylation at tumor-suppressor and longevity gene loci. Ca-AKG restores the cofactor supply, directly enabling active DNA demethylation.
When Ca-AKG earns a stack slot
Ca-AKG has clear value when two or more apply:
- Age 45+ with mitochondrial dysfunction as a top hallmark
- Epigenetic age is a priority metric (running methylation clock testing)
- Running the NAD+ Mito Stack — Ca-AKG is the metabolic flux leg
- Collagen/connective tissue quality is a concern (TCA-dependent collagen hydroxylation)
Skip or defer: if you're on diabetes medications without physician oversight (AKG affects glucose metabolism); if budget is tight, prioritize GlyNAC or NMN first and add Ca-AKG at week 12.
Evidence summary
| Study | Design | Population | Key outcomes | Tier |
|---|---|---|---|---|
| Shahmirzadi 2020 (PMID 32877690) | Controlled feeding | C57BL/6J mice | +12% median lifespan (F), ↓ frailty index | A |
| [PMID 34847066] 2024 | Open-label human | Middle-aged adults, 12 wk | ↑ AKG levels, ↓ inflammatory cytokines, ↓ clock age | B |
| Gibson 2015 | Mechanistic | In vitro | TET cofactor role in epigenetic reprogramming | — |
| Su 2019 | Animal | C. elegans | AKG extends lifespan via AMPK/mTOR signaling | — |
← Swipe for more columns →
Consensus: Tier A for preclinical lifespan extension (mouse data is clean and replicated). Human data is emerging — the 2024 Aging Cell study is promising but smaller. AKG's role as a TET/JMJ cofactor is mechanistically established and independent of any single trial. No completed large RCT in healthy humans for longevity endpoints.
Where Ca-AKG disappoints
- The human evidence is thin. The main human study is small and open-label (no placebo, no blinding) — most of the "A" rests on mouse data, and open-label biological-age improvements are exactly the kind of result placebo control often shrinks. - The mouse lifespan effect was mainly in females. Median lifespan extension was significant in female mice; males benefited on frailty more than lifespan. Extrapolating a single number to all humans overstates it. - The epigenetic-clock readout is a proxy, not an outcome. "Trending younger" on a methylation clock is encouraging but is not the same as living longer or healthier — the clocks themselves are still being validated.
Ca-AKG vs AKG vs free acid: Calcium salt form improves oral bioavailabilityHow much of a compound actually reaches your bloodstream and tissues after you take it. Full glossary → and stability. The free acid AKG is more acidic and GI-harsh at higher doses. Calcium form is the standard for supplementation. Worth stating plainly: the calcium here is a delivery decision, not a mechanism — it buffers the acid and improves stability, but it contributes nothing to AKG's biology. Every effect described above comes from the α-ketoglutarate anion. That anion also clears quickly, with a plasma half-life on the order of minutes, which is why supplementation is about sustaining a steady daily supply of cofactor rather than chasing a single high peak.
Should you add Ca-AKG to your stack?
Mitochondrial or epigenetic hallmark is a priority for you?
node | On diabetes medication or have metabolic syndrome?
redflag | Physician oversight — AKG affects glucose metabolism and insulin signaling
Start 1 g AM with breakfast week 1; titrate to 2 g if tolerated at week 4
node | Running NMN and want the full NAD+ Mito Stack?
Add Ca-AKG week 3 of ramp-in (see NAD+ Mito Stack guide)
Prioritize Zone 2 + sleep + GlyNAC before adding Ca-AKG — lower ROI without foundation
If GI symptoms (loose stool at 2 g), split AM/PM; confirmed GI intolerance → stay at 1 g
Educational decision aid — a way to organize the evidence, not a prescription. Doses and timing shown are those used in studies; confirm anything you act on with a clinician or pharmacist.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 1 g AM → 2 g at week 4 | Mouse study dose-translated; 2 g is metabolically meaningful in humans |
| Form | Calcium AKG | Avoid magnesium or potassium salt forms without reason — Ca form is most studied |
| Timing | AM with breakfast | Glucose metabolism context; take with food to minimize GI sensitivity |
| Duration | 12–24 weeks | Epigenetic effects measured at 12 wk in human data |
| Cycling | Continuous | No cycling data; evidence supports sustained use |
NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → Mito Stack ramp-in schedule
| Week | Time | Compound | Dose |
|---|---|---|---|
| 1–2 | AM fasted | NMN | 250 mg |
| 3+ | AM breakfast | Ca-AKG | 1 g → 2 g |
| 4+ | PM dinner | Resveratrol | 150–250 mg |
← Swipe for more columns →
Titration checklist
- [ ] Start at 1 g; confirm no GI sensitivity before escalating
- [ ] Log fasting glucose at baseline and week 4 if metabolic history
- [ ] Take with breakfast — fat slows absorption and reduces GI distress
- [ ] If 2 g causes loose stool: split to 1 g AM + 1 g PM
- [ ] Combine with NMN before adding resveratrol (standard Mito Stack ramp-in)
Add Ca-AKG to your stack
Toggle Ca-AKG in the NAD+ Mitochondrial Stack preset and watch epigenetic hallmark coverage update.
Open Stack ArchitectMonitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| NAD+ index | 80+ | Baseline, 4 wk, 12 wk | Pair with NMN if below 80 |
| Fasting glucose | <100 mg/dL | Baseline + 4 wk | AKG can lower glucose — monitor in MetSyn |
| hs-CRP | <1.0 mg/L | 3–6 months | 2024 human data showed ↓ cytokines |
| Subjective energy | Daily 1–10 | Ongoing | TCA flux effect should be noticeable in week 4+ |
| Methylation age (optional) | Trending younger | Baseline, 12 mo | TruDiagnostic or similar clock; early proxy for epigenetic effect |
← Swipe for more columns →
AKG blood levels
~100 µM (age 65)
hs-CRP
Elevated
Epigenetic clock score
Baseline
Subjective energy
5–6/10
AKG blood levels
Elevated trend
hs-CRP
Trending down
Epigenetic clock score
Trending younger
Subjective energy
6–8/10
Track epigenetic and metabolic markers
Log fasting glucose, NAD+, and hs-CRP at baseline and week 12.
Open Labs hubSafety, red flags, and contraindications
- Generally well tolerated at 1–2 g in human studies
- GI sensitivity at high doses — loose stool most common; split dose resolves in most cases
- Glucose lowering effect — beneficial in MetSyn, but a risk in medication users
Do not self-start without physician review
- Diabetes medications (insulin, metformin, sulfonylureas) — AKG directly affects glucose metabolism; additive hypoglycemia risk
- Kidney disease (eGFR < 60) — TCA cycle intermediates are renally cleared; physician clearance required
- Active cancer treatment — AKG is a substrate in rapidly proliferating cells; oncologist approval needed
- Pregnancy or breastfeeding — no safety data; avoid
Soft cautions
At doses above 2 g: loose stool, bloating, transient nausea. Split dosing (AM + PM) resolves in most cases. Reduce to 1 g if GI intolerance persists beyond week 2.
What would change this grade. Ca-AKG's A is preclinical — it would earn a human-grade A with a placebo-controlled RCT confirming the epigenetic and metabolic signals under blinding, ideally with a hard endpoint. It would fall if the female-skewed mouse effect and open-label human results don't hold up in controlled trials.
Who should skip Ca-AKG
- Anyone on insulin, metformin, or sulfonylureas without oversight — AKG affects glucose metabolism; additive hypoglycemia risk. - Kidney disease (eGFR <60) or active cancer treatment — renal clearance and proliferating-cell substrate concerns; get clearance. - Budget-limited stackers — add it after NMN/GlyNAC; alone it's a lower-ROI leg.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| NMN | Ca-AKG (TCA flux) + NMN (NAD+ fuel) address mitochondrial dysfunction from two independent axes | NAD+ Mito Stack |
| Resveratrol | Ca-AKG fuels the metabolic context; resveratrol activates SIRT1 biogenesis — TCA flux + biogenesis signal | NAD+ Mito Stack |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Glucose-lowering medication | AKG's own glucose-lowering can stack into hypoglycemia | Coordinate with your prescriber; monitor fasting glucose |
| — | No well-characterized supplement antagonists at 1–2 g | Co-stacks freely; the real limiters are renal clearance and GI tolerance |
Personal results template
My Ca-AKG results log
Copy to your notes or Labs hub. Update at baseline, week 4, week 12, and week 24.
| Date | Week | Dose | Fasting glucose | hs-CRP | Energy (1–10) | AKG (if tested) | Notes |
|---|---|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | 1 g | — | — | — | — | Baseline |
| YYYY-MM-DD | 4 | 1–2 g | — | — | — | — | GI check + titration |
| YYYY-MM-DD | 12 | 2 g | — | — | — | — | Primary checkpoint |
| YYYY-MM-DD | 24 | 2 g | — | — | — | — | Extended endpoint |
← Swipe for more columns →
Response criteria (personal): - Meaningful: Fasting glucose stable + hs-CRP trending down + energy ↑1–2 points at 12 wk - Plateau: No changes at 24 wk → confirm dose compliance and pair with NMN - Adverse: GI intolerance past week 2 → split dose; hypoglycemia → consult prescriber for medication adjustment
See the full NAD+ Mitochondrial Stack
Ca-AKG's clearest use case: the TCA flux leg of the three-compound mitochondrial architecture.
Read synergy guideReferences
- Asadi Shahmirzadi A et al. Alpha-ketoglutarate extends lifespan in mice. Cell Metabolism (2020). PMID 32877690
- Demidenko O et al. Ca-AKG reduces biological age in middle-aged adults. Aging Cell (2024). PMID 34847066
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.